Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 3, 2011, Pages 681-688

  Søndergaard, Esben ^a   Klose, Marianne ^b   Hansen, Mette ^c   Hansen, Birgit Sehested ^d   Andersen, Marianne ^c   Feldt Rasmussen, Ulla ^b   Laursen, Torben ^a   Rasmussen, Michael Højby ^d   Christiansen, Jens Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; NNC 126 0083; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; INJECTION SITE ERYTHEMA; INSULIN BLOOD LEVEL; LIPOATROPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION;

ADULT; AGED; AREA UNDER CURVE; BODY COMPOSITION; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 79952289185     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1931     Document Type: Article

References (30)

1. Vance ML, Mauras N 1999 Growth hormone therapy in adults and children. N Engl J Med 341:1206-1216 (Pubitemid 29480660)
2. Simpson H, Savine R, Sönksen P, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Cohen P, Hintz R, Ho K, Mullis P, Robinson I, Strasburger C, Tanaka T, Thorner M 2002 Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res 12:1-33 (Pubitemid 35021230)
3. Laursen T, Gravholt CH, Heickendorff L, Drustrup J, Kappelgaard AM, Jørgensen JO, Christiansen JS 2001 Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab 86:1222-1228
4. Desrosiers P, O'Brien F, Blethen S 2005 Patient outcomes in the GH Monitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev 2(Suppl 3):327-331 (Pubitemid 40469491)
5. Kapoor RR, Burke SA, Sparrow SE, Hughes IA, Dunger DB, Ong KK, Acerini CL 2008 Monitoring of concordance in growth hormone therapy. Arch Dis Child 93:147-148 (Pubitemid 351204756)
6. Rosenfeld RG, Bakker B 2008 Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 14:143-154
7. Veronese FM, Pasut G 2005 PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451-1458 (Pubitemid 41483874)
8. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D 2007 PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35:9-16 (Pubitemid 46036470)
9. Hamidi M, Rafiei P, Azadi M 2008 Designing PEGylated therapeutic molecules: advantages in ADMET properties. Expert Opin Drug Discov 11:1293-1307
10. Rasmussen MH, Bysted BV, Anderson TW, Klitgaard T, Madsen J 2010 Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. J Clin Endocrinol Metab 95:3411-3417
11. Rasmussen MH, Jensen L, Anderson TW, Klitgaard T, Madsen J 13 August 2010 Multiple doses of pegylated long-acting growth hormone is well tolerated in healthy male volunteers and possesses a potential once-weekly treatment profile. Clin Endocrinol (Oxf) 10.1111/j.1365-2265.2010.03863.x
12. Ho KK 2007 Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157:695-700
13. World Medical Association Declaration of Helsinki 2008 Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964; latest amendment made by the 59th WMA General Assembly, Seoul, October 2008
14. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Müller J, Skakkebaek NE 1995 Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 80:2534-2542
15. Smith SL, Hindmarsh PC, Brook CG 1993 Compliance with growth hormone treatment: are they getting it? Arch Dis Child 68:91-93
16. Reiter EO, Attie KM, Moshang Jr T, Silverman BL, Kemp SF, Neuwirth RB, Ford KM, Saenger P 2001 A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J Clin Endocrinol Metab 86:4700-4706 (Pubitemid 33020508)
17. Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM 2002 A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab 15(Suppl 2):715-722 (Pubitemid 34700345)
18. Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B 2005 Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab 90:6431-6440 (Pubitemid 41759296)
19. Touraine P, D'Souza GA, Kourides I, Abs R, Barclay P, Xie R, Pico A, Torres-Vela E, Ekman B; GH Lipoatrophy Study Group 2009 Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol 161:533-540
20. Laursen T, Jørgensen JO, Jakobsen G, Hansen BL, Christiansen JS 1995 Continuous infusion versus daily injections of growth hormone deficiency (GH) for 4 weeks in GH-deficient patients. J Clin Endocrinol Metab 80:2410-2418
21. Iranmanesh A, Grisso B, Veldhuis JD 1994 Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 78:526-535 (Pubitemid 24083287)
22. Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB 2006 Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 91:2047-2054 (Pubitemid 43854980)
23. Jørgensen JO, Pedersen SA, Thuesen L, Jørgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1:1221-1225 (Pubitemid 19140325)
24. Avan der Klaauw A, Romijn JA, Biermasz NR, Smit JWA, van Doorn J, Dekkers OM, Roelfsema F, Pereira AM 2006 Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 155:701-708 (Pubitemid 44857494)
25. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R 2002 The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomised controlled multicenter trial. J Bone Miner Res 17:1081-1094 (Pubitemid 34535147)
26. Laursen T 2004 Clinical pharmacological aspects of growth hormone administration. Growth Horm IGF Res 14:16-44 (Pubitemid 38094240)
27. Johansson JO, Oscarsson J, Bjarnason R, Bengtsson BA 1996 Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis. Metabolism 45:362-369
28. Oscarsson J, Ottosson M, Johansson JO, Wiklund O, Mårin P, Björntorp P, Bengtsson BA 1996 Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity. Metabolism 45:370-377
29. Laursen T, Lemming L, Jørgensen JO, Klausen IC, Christiansen JS 1998 Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients. Horm Res 50:284-291 (Pubitemid 29041363)
30. Tauber M, De Bouet Du Portal H, Sallerin-Caute B, Rochiccioli P, Bastide R 1993 Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GH-deficient children. J Clin Endocrinol Metab 76:1135-1139